MAS
ALNY icon

Meeder Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Meeder Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$613K Buy
1,853
+15
+0.8% +$5.1K 0.03% 359
2025
Q4 		$731K Sell
1,838
-51
-3% -$22.6K 0.03% 331
2025
Q3 		$861K Buy
1,889
+764
+68% +$311K 0.04% 295
2025
Q2 		$367K Buy
1,125
+147
+15% +$40.7K 0.02% 440
2025
Q1 		$264K Buy
978
+72
+8% +$18.5K 0.02% 483
2024
Q4 		$213K Sell
906
-27
-3% -$7.1K 0.01% 525
2024
Q3 		$257K Buy
+933
New +$243K 0.02% 473

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Advisory Services's ALNY Position: Q1 2026 in Review

Meeder Advisory Services increased its Alnylam Pharmaceuticals (ALNY) stake by 0.82% in Q1 2026, buying an estimated $5.1K and bringing the position to 1,853 shares worth $613K. The position accounts for 0.03% of the portfolio, ranked #359.

Meeder Advisory Services first reported a position in ALNY in Q3 2024 and has held it in 7 quarters since. The position peaked at $861K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Meeder Advisory Services held 1,853 shares of Alnylam Pharmaceuticals worth $613K as of Q1 2026.
  • Meeder Advisory Services bought 15 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.1K.
  • Alnylam Pharmaceuticals made up 0.03% of Meeder Advisory Services's portfolio in Q1 2026, its #359 holding.
  • Meeder Advisory Services first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Meeder Advisory Services's Alnylam Pharmaceuticals position peaked at $861K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Meeder Advisory Services's 13F filing for Q1 2026, filed 7 May 2026.